# Regentis Biomaterials

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regentis-biomaterials

- Industry: Materials
- Headquarters: Or Akiva, Israel
- Website: www.regentis.co.il
- Total disclosed funding: $33M
- Latest round: Series D (Feb 7, 2016)
- Investors on record: 8

## About

Regentis Biomaterials Ltd. develops innovative hydrogel-based implants aimed at orthopedic applications, focusing on enhancing tissue regeneration and repair through advanced medical technologies.Founded in 2004 in Or Akiva, Israel, Regentis Biomaterials specializes in hydrogel solutions for orthopedic tissue repair. The company has closed four funding deals, including the latest Series D round in February 2016, raising USD 15 mn led by Xizang Haisco Pharmaceutical Group Co., Ltd. The founder's prior entrepreneurial experiences are not disclosed, and there is no mention of subsidiaries or significant pivots in their strategy since inception.Regentis Biomaterials primarily focuses on the development of GelrinC, a resorbable hydrogel designed for orthopedic applications to assist in tissue repair. GelrinC provides a supportive matrix, promoting cellular infiltration and regeneration. Their clients include healthcare providers and hospitals across Europe, North America, and parts of Asia, where they aim to improve recovery outcomes for orthopedic injuries.The company generates revenue through B2B sales of GelrinC implants to healthcare institutions involved in orthopedic surgeries. Their pricing aligns with industry standards, and they maintain relationships with medical professionals to secure ongoing supply agreements. Regentis reported an EBITDA of USD -668,000 for the most recent year, which was 2021.Having raised USD 15 mn in Series D funding in February 2016, Regentis Biomaterials plans to utilize these resources to expand its market reach into China and support clinical trials for GelrinC in the United States. The company is actively seeking to introduce new products and enhance its geographical footprint in additional markets by targeting specific regions for expansion.

## Funding rounds

- Series D, Feb 7, 2016, $15M — SCP Vitalife Partners, Medica Venture Partners, Technion Research & Development Foundation, Generali Investments, Xizang Haisco Pharmaceutical Group Co., Ltd, Technion Investment Opportunity Fund
- Series C, May 14, 2012, $10M — SCP Vitalife Partners, Medica Venture Partners, Koninklijke DSM N.V., Generali Group
- Series B, Aug 21, 2007, $7.5M — SCP Vitalife Partners, Medica Venture Partners

## Investors

- SCP Vitalife Partners (https://capitalatlas.ai/funds/scp-vitalife-partners) — Series B, Series C, Series D
- Medica Venture Partners (https://capitalatlas.ai/funds/medica-venture-partners) — Series B, Series C, Series D
- Koninklijke DSM N.V. — Series C
- Generali Group — Series C
- Technion Research & Development Foundation — Series D
- Generali Investments — Series D
- Xizang Haisco Pharmaceutical Group Co., Ltd — Series D
- Technion Investment Opportunity Fund — Series D